Predictive Modeling and Mendelian Randomization for Identifying HCC Patients with High Response to TACE with Atezolizumab and Bevacizumab
We developed a predictive model for TACE+Atez/Bev therapy, enabling effective patient screening. MR validated <i>PDCD1</i>'s role in HCC immunotherapy at the genetic level.
Authors
- W. Chen
- Shuxian Chen
- Kai Shi
- Yuhui Shi
- Nan Lin
- Jiehui Tan (ORCID: https://orcid.org/0009-0001-1545-2857)
- Jiawei Liu
- Ruinan Xia
- Shuyan Li
Institutions
- Sun Yat-sen University (CN)
- Guangzhou Liwan District Traditional Chinese Medicine Hospital (CN)
- Zhongshan People's Hospital (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/jhc.s554788
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Guangdong Province